Chemotherapy News and Research

Latest Chemotherapy News and Research

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to destroy heart tissue, as well as tumors, in some patients.

29 Oct 2012

Research roundup: Patients' unrealistic expectations for chemo; Neighborhood may affect CPR rates; Rate hike reviews working

"To make informed decisions about whether to receive chemotherapy, patients with advanced lung or colorectal cancer need a realistic understanding of its likely benefits," the authors write. Researchers conducted comprehensive reviews of records.

29 Oct 2012

Rectal cancer more likely to spread to the lymph nodes in younger patients

Rectal cancer is more likely to spread to the lymph nodes in younger patients, according to new findings that Fox Chase Cancer Center researchers will be presenting on October 29 at the American Society for Radiation Oncology's 54th Annual Meeting.

29 Oct 2012

Viewpoints: Medicare provider cuts 'won't work'; A 'pamphlet isn't a plan'

Once the presidential election is over, Congress will try to address the Medicare cost shortfall one way or another. They will almost certainly consider a method that is guaranteed to fail: Medicare rate cuts for doctors and hospitals. It's been tried before, most notably as part of the 1997 Balanced Budget Act. Not once since the BBA required annual physician rate cuts have those cuts been implemented, leading every year to the predictable and depressing final-hours "doc fix" vote.

26 Oct 2012

Longer looks: Controversial raffle for IVF treatment; New role for community health workers; Romney, health care and the free market

"That's right, one lucky woman will win the ultimate chance at starting or building her family," said a contest announcement issued in April by Long Island I.V.F., a clinic in Melville that offers in vitro fertilization to women who are having difficulty conceiving. Contestants were asked to submit "the most emotional or entertaining essays and homemade amateur videos" explaining why they wanted a free round of I.V.F.

26 Oct 2012

FDA accepts ARIAD’s ponatinib NDA for filing

ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

25 Oct 2012

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer.

25 Oct 2012

Medication at end of life indicates care quality

Medication given to patients at the end of life varies according to whether they are being cared for in a hospice or hospital, and has the potential to indicate the quality of their care, suggest researchers.

24 Oct 2012

Pleiotrophin protein may be long-sought growth factor for blood stem cells

Duke Medicine researchers studying the interaction of blood stem cells and the niche where they reside have identified a protein that may be a long-sought growth factor for blood stem cells.

24 Oct 2012

Bodyguard macrophages protect stem cells from over-differentiation

Hiding deep inside the bone marrow are special cells. They wait patiently for the hour of need, at which point these blood forming stem cells can proliferate and differentiate into billions of mature blood immune cells to help the body cope with infection, for example, or extra red blood cells for low oxygen levels at high altitudes. Even in emergencies, however, the body keeps to a long-term plan: It maintains a reserve of undifferentiated stem cells for future needs and crises.

23 Oct 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

Liquid version of breast cancer drug Tamoxifen launched in the US

Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month's activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease.

22 Oct 2012

Research director at Kessler Foundation awarded NIH grant to study effects of chemotherapy on brain

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a grant by the National Institutes of Health to study the effects of chemotherapy on brain structure, neurophysiology, and psychomotor behavior.

20 Oct 2012

Study describes design and effectiveness of NIR responsive gold nanorods for chemotherapy

Excitement around the potential for targeted nanoparticles (NPs) that can be controlled by stimulus outside of the body for cancer therapy has been growing over the past few years. More specifically, there has been considerable attention around near-infrared (NIR) light as an ideal method to stimulate nanoparticles from outside the body.

19 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Minnelide gives new hope for patients with pancreatic cancer

A new drug created at the University of Minnesota may hold the answer to defeating pancreatic cancer, according to results published today in the prestigious journal Science Translational Medicine.

19 Oct 2012

DNA damage response contains previously unknown components: Study

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida; Duke University; Johns Hopkins University; the Brazilian National Cancer Institute; and the Rio de Janeiro Federal Institute of Education, Science and Technology have discovered that an intricate system to repair DNA damage called the "DNA damage response" (DDR) contains previously unknown components, including proteins that could be targeted as sensitizers for chemotherapy.

17 Oct 2012

UMB, UMCP to develop small robot that could help neurosurgeons in removing brain tumors

A research team from the University of Maryland, College Park (UMCP) and the University of Maryland, Baltimore (UMB) have been awarded a new $2 million grant from the National Institutes of Health (NIH) to continue developing a small robot that could one day be a huge aid to neurosurgeons in removing difficult-to-reach brain tumors.

17 Oct 2012

FDA accepts A.P. Pharma’s resubmission of NDA for APF530

A.P. Pharma, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of its New Drug Application (NDA) for APF530.

17 Oct 2012

Brachyury variation may increase risk of chordoma

A genetic variation possessed by 40% of the population is associated with a five-fold increase in risk for developing chordoma, a cancer that strikes the bones of the skull and spine.

17 Oct 2012